Data protection Impressum

Medtech

TheraMe!, a Lausanne-based medtech, is transforming cancer treatment by partnering with CSEM to develop an automated, microfluidic-based instrument. This breakthrough technology enables personalized drug screening on live tumor samples, providing cancer patients with tailored therapy recommendations before treatment begins.

CSEM and TheraMe! transform cancer therapy with personalized drug screening technology

28 January 2025

EPFL Innovation Park biotech company AB2 Bio has signed an option and licensing agreement with Japan-based Nippon Shinyaku to advance Tadekinig alfa, a novel treatment for Primary Monogenic IL-18 driven Hyperinflammatory Syndrome. The deal includes up to USD 36 million in early payments and milestone-based funding of up to USD 650 million.

AB2 Bio secures USD 650 million partnership with Nippon Shinyaku for rare disease therapy

27 January 2025

EBAMed has secured an additional EUR 1.6 million in Series A funding, bringing the total raised to EUR 16 million. This new investment, contributed by CDP Venture Capital and the European Union, supports the development of EBAMed’s groundbreaking CardioKit system for non-invasive treatment of heart arrhythmias using Proton Therapy.

Geneva medtech EBAMed completes financing round with EUR 16 million

27 January 2025

Geneva-based BrainScape Medical, a newly incorporated company specializing in neuromonitoring and neurostimulation technologies, has announced several milestones, including new leadership, FDA Breakthrough Device Designation, and promising results from its first human trials.

BrainScape Medical makes strides in long-term brain monitoring

21 January 2025

Start-up Aspivix has raised EUR 1.95 million through a crowdfunding campaign to advance the commercialization of its innovative gynecological device, Carevix™. The campaign, hosted on the Capital Cell platform, aims to reach a target of EUR 2.15 million by 15 March 2025.

Medtech Aspivix secures EUR 1.95 million in crowdfunding

20 January 2025

Actival, a medtech spin-off from CSEM, has received CHF 150,000 from Venture Kick to launch its Active Aligners, a groundbreaking solution addressing the hygiene challenges of traditional clear aligners.

Neuchâtel’s Actival receives Venture Kick support to launch its innovative dental aligners

8 January 2025

Vanarix, a Biopôle-based start-up specializing in cartilage regeneration, has received Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for its bioengineered cartilage mini-implants, Cartibeads.

Vanarix secures FDA Orphan Drug designation for its Cartibeads

7 January 2025

ONWARD Medical has achieved a significant milestone with FDA de novo classification and market authorization for its non-invasive ARC-EX System, the first technology approved to enhance hand strength and sensation after chronic spinal cord injury.

ONWARD Medical receives FDA authorization for its spinal cord stimulation system

6 January 2025

Spirecut, a Swiss medtech pioneer in ultrasound-guided hand surgery, has inaugurated Switzerland’s first Center of Excellence at the Clinique de la Main in Geneva. The center aims to train surgeons in the SonoSurgery technique while supporting research into new applications for Spirecut’s Sono-Instruments®.

Spirecut opens Switzerland’s first Center of Excellence for ultrasound-guided hand surgery

17 December 2024

Limula, Actival, and AirCurve have received funding from the FIT to advance groundbreaking solutions in cell therapy production, dental health, and tracheal intubation. Limula secured a CHF 500,000 Tech Growth loan, while Actival and AirCurve each received CHF 100,000 Tech Seed loans.

Western Switzerland healthcare start-ups Limula, Actival, and AirCurve secure FIT funding

16 December 2024

1 … 3 4 5 6 7 8 9 10 11 … 15